References
- Zhuo Z, Yan C, Hongbin M, et al. Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide. Leuk Lymphoma 2013;54:2041–2046
- Matthews V, George B, Lakshmi K, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107:2627–2632.
- Iland H, Bradstock K, Supple S, et al;the Australasian, Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and intravenous arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 2012;120:1570–1580.
- dé The H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010;10:775–783.
- Chen S-J, Zhou G-B, Zhang X-W, et al. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 2011;117:6425–6437.
- Aposhian H, Zakharyan H, Avram M, et al. A review of the enzymology of arsenic metabolism and a new potential role of hydrogen peroxide in the detoxication of the trivalent arsenic species. Toxicol Appl Pharmacol 2004;198:327–335.
- Fujisawa S, Ohno R, Shigeno K, et al. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Cancer Chemother Pharmacol 2007;59:485–493.
- Firkin F. Oral administration of arsenic trioxide in the treatment of acute promyelocytic leukaemia and accelerated phase chronic myeloid leukaemia: an Australian single-centre study. Intern Med J 2012;42:948–951.